Abstract
Aim A standard strain of HSV-1 (strain F) and Acyclovir(ACV)-resistant strains HSV-1 (strain 153/BLUE/106) were used to investigate the antiviral activity of Cyanovirin-N (CVN) and its derivatives (LCVN, mPEG10K-ALD-LCVN). Moreover, antiviral mode and mechanism of antiviral of LCVN was studied.
Experimental HSV-1 (strain F) was maintained in our laboratory and propagated in Vero cells. HSV-1 (strain 153/BLUE/106) resistant strains were isolated from children with herpes labial in Guangzhou Children's Hospital. Purified recombinant CVN, LCVN and thePEGylated product 10 K PEGALD-LCVN were prepared in-house by a processmodified as reported previously.Vero cells were maintained in our laboratory and grown in DMEM medium supplemented with 10% FBS, 100 U/mL penicillin and 100 microg/mL streptomycin. Cytopathic effect (CPE) and MTT assays were used to evaluate the effect of CVN and itsderivatives on HSV-1 in Vero cells. The number of copies of HSV-DNA was detected by real-time fluorescence quantitative PCR (FQ-PCR).
Result and discussion The results showed that CVN, LCVN and mPEG10K-ALD-LCVN had a low cytotoxicity on Vero cells with a median lethal concentration (TC50) of 1.456±0.340 microM1.747±0.097 microM 9.48±1.403 microM respectively; LCVN and mPEG10K-ALD-LCVN completely inhibit viral infection at the concentration of 0.1 microM and 2 microM respectively. The antiviral activity of CVN, LCVN and mPEG10K-ALD-LCVN were stronger than acyclovir significantly at Low micromolar. The effect of inhibiting viral attachment and penetration of LCVN were modest whereas thetreatment after virus infection was noticeable. The results showed that LCVN cannot inhibit the transcription of immediate early gene (UL54), but it can significantly inhibit transcription of the late gene (UL27), thereby inhibiting viral proliferation.
Conclusion It is easy for the nucleoside analogue to develop drug-resistant strains following long period of treatment, whereas LCVN can inhibit HSV-1 and its ACV-resistant strains though multiple mechanisms. Thus, LCVN is an effective drug for HSV-1 and its ACV-resistant strains.
Keywords
References
Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses.Clin Infect Dis. 1998;26:541–553.
Waggoner-Fountain LA, Grossman LB. Herpes simplex virus.Pediatr Rev. 2004;25:86–93.
Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, McMahon JB, et al. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif. 1998;12:151–158.
Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother.1997;41:1521–1530.
Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother. 2005;49:1055–1059.
Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Antiviral Res. 2007;73:147–150.
Russell DB, Tabrizi SN, Russell JM, Garland SM. Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting. J Clin Virol.2001;22:305–313.
Severson JL, Tyring SK. Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol.1999;135:1393–1397.
Gustafson KR, Sowder RC, Henderson LE, Cardellina JH, McMahon JB, Rajamani U, et al. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-n, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem Biophys Res Commun. 1997;238:223–228.
Bewley CA, Gustafson KR, Boyd MR, Covell DG, Bax A, Clore GM, et al. Solution structure of cyanovirin-N, a potent HIVinactivating protein. Nat Struct Biol. 1998;5:571–578.
Bolmstedt AJ, O’Keefe BR, Shenoy SR, McMahon JB, Boyd MR. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol. 2001;59:949–954.
Han Z, Simpson JT, Fivash MJ, Fisher R, Mori T. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein. Peptides.2004;25:551–561.
Wu C, Chen W, Chen J, Han B, Peng Z, Ge F, et al. Preparation of monoPEGylated Cyanovirin-N’s derivative and its anti-influenza A virus bioactivity in vitro and in vivo. J Biochem. 2015;157:539–548.
Chen J, Huang D, Chen W, Guo C, Wei B, Wu C, et al. Linker extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 by targeting the glycan ligand. PLoS One. 2014;9:e86455.
Gao X, Chen W, Guo C, Qian C, Liu G, Ge F, et al. Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion. Appl Microbiol Biotechnol.2010;85:1051–1060.
Campling BG, Pym J, Galbraith PR, Cole SP. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk Res. 1988;12:823–831.
Gross G. [Herpes simplex virus infections]. Hautarzt.2004;55:818–830.
Tiwari V, Shukla SY, Shukla D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion.Antiviral Res. 2009;84:67–75.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.